glp-1 gip muscle preservation therapies 2025 Glucagon-like peptide-1 receptor agonists and mass effects GLP-1 Clinical Practice Updates: September

In a study of Wegovy in people with or without type 2 diabetes, people taking 1.7 mg and 2.4 mg dosages lost an average of 2% of their body weight after one month

By logging things consistently, patterns become clear

Aging populations, sedentary lifestyles, and urbanization contribute to increasing rates of metabolic disorders, creating a larger target patient pool for GLP-1 therapies

Most required prior authorization

But plaintiffs counter that their lawsuit details a much broader scheme of deceptive marketing, negligent misrepresentation, breach of warranty, and design defect

Most patients notice reduced appetite within 23 weeks of starting GLP-1 therapy, though measurable weight loss typically emerges after 46 weeks as your body adjusts to smaller portion sizes and reduced calorie intake